Top Markets
Coin of the day
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
Rankning i aktier #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
Aktiekurs
$0.00156067
Senast synkroniserad: 2024-05-03
Marknadsvärde
$182.87K
Förändring (1 dag)
-72.69%
Förändring (1 år)
0.00%
Land
CH
Handel ObsEva S.A. (OBSN)

Kategori

Utdelningsavkastning för ObsEva S.A. (OBSN)
Utdelningsavkastningen (TTM) för ObsEva S.A. (aktiesymbol: OBSN) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för ObsEva S.A. (OBSN) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter